Phase 2, Open Label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in Patients With Advanced and/or Unresectable Non-Small Cell Lung Cancer (NSCLC), With Biomarker Analysis to Characterize Response to Therapy
Latest Information Update: 05 Jul 2024
At a glance
- Drugs Datopotamab deruxtecan (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ICARUS-LUNG01
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 01 Jul 2021 New trial record